Core Insights - Envista (NVST) reported $601 million in revenue for Q3 2024, a year-over-year decline of 4.8%, with an EPS of $0.12 compared to $0.43 a year ago, exceeding the Zacks Consensus Estimate of $592.28 million by 1.47% and delivering an EPS surprise of 33.33% [1] Revenue Performance - North America sales were $319.50 million, below the average estimate of $324.05 million, reflecting a year-over-year decline of 3.8% [3] - Western Europe sales reached $109.30 million, compared to the estimated $119.67 million, marking an 8.5% decrease year-over-year [3] - Emerging markets generated $140.90 million, surpassing the average estimate of $124.46 million, but still showing a 5.7% decline year-over-year [3] - Other developed markets reported $31.30 million, exceeding the estimate of $28.93 million, with a year-over-year increase of 3% [3] Segment Analysis - Specialty Products & Technologies in North America generated $165.30 million, slightly below the estimate of $170.18 million, reflecting a 2.8% decline year-over-year [3] - Equipment & Consumables in emerging markets reported $31.40 million, exceeding the estimate of $23.63 million, but showing a significant 16% decline year-over-year [3] - Specialty Products & Technologies in other developed markets reached $21.70 million, slightly above the estimate of $21.05 million, with a year-over-year decline of 1.4% [3] - Equipment & Consumables in North America reported $154.20 million, slightly above the estimate of $153.87 million, reflecting a 4.8% decline year-over-year [3] - Equipment & Consumables in Western Europe reached $24.10 million, exceeding the estimate of $21.83 million, with no change year-over-year [3] Stock Performance - Envista's shares have returned -2.8% over the past month, while the Zacks S&P 500 composite has increased by 1.8%, with the stock currently holding a Zacks Rank 3 (Hold) [4]

Core Insights - Envista (NVST) reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of $0.09 per share, but down from $0.43 per share a year ago, indicating an earnings surprise of 33.33% [1] - The company generated revenues of $601 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 1.47%, but down from $631.3 million year-over-year [2] - Envista has underperformed the market, with shares down approximately 21.9% year-to-date compared to the S&P 500's gain of 22.3% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $647.76 million, and for the current fiscal year, it is $0.69 on revenues of $2.5 billion [7] - The estimate revisions trend for Envista is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Products industry, to which Envista belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - The performance of Envista's stock may be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and earnings estimate revisions [5]

Core Viewpoint - The market anticipates a year-over-year decline in Envista's earnings due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1] Earnings Expectations - Envista is expected to report quarterly earnings of $0.09 per share, reflecting a year-over-year decrease of 79.1% [2] - Projected revenues for the quarter are $592.28 million, down 6.2% from the same quarter last year [2] Estimate Revisions - The consensus EPS estimate has been revised 3.77% higher in the last 30 days, indicating a reassessment by analysts [3] - The Most Accurate Estimate for Envista is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.86% [6] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading can indicate a likely earnings beat, particularly when combined with a strong Zacks Rank [4][5] - Envista currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat despite the positive Earnings ESP [6] Historical Performance - In the last reported quarter, Envista was expected to post earnings of $0.27 per share but only achieved $0.11, resulting in a surprise of -59.26% [7] - The company has not beaten consensus EPS estimates in any of the last four quarters [7] Conclusion - While an earnings beat could influence stock movement, other factors may also play a significant role in stock performance [8] - Envista does not appear to be a strong candidate for an earnings beat, suggesting investors should consider additional factors before making decisions [8]

Core Viewpoint - Envista Holdings Corporation is set to report its financial results for the third quarter of 2024 on October 30, 2024, with a conference call scheduled for the same day to discuss these results [1][2]. Company Overview - Envista is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, focused on improving lives through dental care [4]. - The company provides a comprehensive portfolio of dental products, including dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs for dental professionals [4]. - Envista is recognized as one of the largest global dental products companies, holding significant market positions in attractive segments of the dental products industry [4].

Group 1 - Envista Holdings Corporation will participate in the Baird 2024 Global Healthcare Conference on September 11, 2024, from 10:50 – 11:20 am ET [1] - The company is a global family of over 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr [2] - Envista aims to improve lives by partnering with professionals to enhance patient care through industry-leading dental consumables, solutions, technology, and services [2] Group 2 - Envista's comprehensive portfolio includes dental implants, orthodontics, and digital imaging technologies, addressing a wide range of clinical needs [2] - The company is recognized as one of the largest global dental products companies, holding significant market positions in attractive segments of the dental products industry [2]

Core Insights - Envista's international operations are crucial for assessing its financial strength and growth potential, especially given its global presence [1][2] Group 1: Financial Performance - For the quarter ending June 2024, Envista reported total revenue of $633.1 million, a decline of 4.4% year over year [4] - Western Europe contributed 21.7% of total revenue, amounting to $137.5 million, which was a surprise decline of 5.88% compared to expectations [5] - Other developed markets generated $28.7 million, representing 4.5% of total revenue, also falling short of the consensus estimate by 11.63% [6] Group 2: Revenue Projections - Analysts project total revenue for the current fiscal quarter to be $612.2 million, reflecting a 3% decline from the same quarter last year [7] - For the full year, total revenue is expected to reach $2.53 billion, indicating a 1.5% decrease from the previous year [8] - Revenue contributions are anticipated to be 20.3% from Western Europe ($124.41 million) and 5% from Other developed markets ($30.84 million) [7] Group 3: Market Dynamics - The reliance on international markets presents both opportunities and challenges for Envista, necessitating close monitoring of revenue trends to forecast future performance [9] - The interconnected global economy and geopolitical tensions are influencing earnings predictions for companies with overseas operations [10]

Core Points - Envista Holdings Corporation reported adjusted earnings per share (EPS) of 11 cents for Q2 2024, a decline of 74.4% year over year, missing the Zacks Consensus Estimate by 59.3% [1] - The company's GAAP loss was $6.69 compared to earnings of 29 cents in the same quarter last year [2] - Revenues totaled $633.1 million, down 4.4% year over year, and missed the Zacks Consensus Estimate by 2.3% [3] Revenue Breakdown - Specialty Products & Technologies segment generated $415.1 million, a decrease of 0.5% year over year [4] - Equipment & Consumables segment revenues fell 11.2% year over year to $218 million [4] Operational Performance - Gross profit decreased by 13.7% year over year to $326.6 million, with gross margin contracting by 557 basis points to 51.6% due to a 4.4% decline in sales and an approximately 8% rise in cost of sales [5] - Operating profit plummeted 99% year over year to $48.1 million, with the operating margin contracting by 1183 basis points to 0.8% [6] Financial Position - Cash and cash equivalents at the end of Q2 2024 were $1.04 billion, up from $948.5 million at the end of Q1 2024 [7] - Long-term debt remained unchanged at $1.39 billion [7] - Year-to-date net cash provided by operating activities was $133.4 million, an increase from $78.2 million a year ago [7] 2024 Guidance - The company expects core sales to decline between 1% and 4% and adjusted EBITDA margins to be in the range of 10%-12% for 2024 [8] - A further decline is anticipated in Q3 before returning to growth in Q4 [8] - The current Zacks Consensus Estimate for full-year revenues is $2.56 billion, suggesting a 0.3% decline from the previous year [8] Market Context - Envista's Spark division reported slowed sales growth due to deferring a larger portion of case revenues, impacting quarterly sales despite case starts growing above market levels [10] - Diagnostics sales contracted in high single digits due to the higher interest rate environment and exiting lower priority, price-sensitive geographic markets [11]

Envista (NVST) reported $633.1 million in revenue for the quarter ended June 2024, representing a year-overyear decline of 4.4%. EPS of $0.11 for the same period compares to $0.43 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $647.99 million, representing a surprise of -2.30%. The company delivered an EPS surprise of -59.26%, with the consensus EPS estimate being $0.27. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

分组1 - Envista reported quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.27 per share, and down from $0.43 per share a year ago, representing an earnings surprise of -59.26% [1] - The company posted revenues of $633.1 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 2.30%, and down from year-ago revenues of $662.4 million [2] - Envista shares have lost about 34.5% since the beginning of the year, while the S&P 500 has gained 9.9% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.30 on revenues of $632.61 million, and for the current fiscal year, it is $1.15 on revenues of $2.56 billion [7] - The Zacks Industry Rank for Medical - Products is currently in the top 42% of over 250 Zacks industries, indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Analysts project that Envista (NVST) will report quarterly earnings of $0.27 per share, reflecting a year-over-year decline of 37.2%, with revenues expected to reach $647.99 million, down 2.2% from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been adjusted downward by 4.2% over the past 30 days, indicating a reassessment by analysts [1][2] Revenue and Sales Projections - Analysts estimate 'Sales- Equipment & Consumables' will reach $233.54 million, a decrease of 4.8% year-over-year [4] - 'Sales- Specialty Products & Technologies' is projected at $414.62 million, reflecting a decline of 0.6% [4] - 'Geographic Sales- North America' is expected to be $337.91 million, down 0.7% from the prior year [4] - 'Geographic Sales- Western Europe' is estimated at $146.09 million, showing a slight increase of 0.8% [5] - 'Geographic Sales- Emerging markets' is projected to be $129.84 million, indicating a significant decline of 10.3% [5] - 'Geographic Sales- Other developed markets' is expected to reach $32.48 million, up 0.6% year-over-year [6] - 'Geographic Sales- Specialty Products & Technologies- North America' is forecasted at $175.23 million, down 1.7% [6] - 'Geographic Sales- Equipment & Consumables- Emerging markets' is estimated at $30.80 million, reflecting a substantial decline of 28.2% [7] - 'Geographic Sales- Specialty Products & Technologies- Other developed markets' is projected at $22.60 million, up 1.8% [7] - 'Geographic Sales- Specialty Products & Technologies- Emerging markets' is expected to be $99.04 million, down 2.8% [8] - 'Geographic Sales- Equipment & Consumables- North America' is projected at $162.68 million, indicating a slight increase of 0.4% [8] - 'Geographic Sales- Equipment & Consumables- Western Europe' is estimated at $29.26 million, down 3.4% [9] Stock Performance - Over the past month, shares of Envista have returned -3.9%, compared to a -6.7% change in the Zacks S&P 500 composite [9] - Currently, NVST holds a Zacks Rank 5 (Strong Sell), suggesting potential underperformance in the near future [9]